Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

NCT02030184 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI has left the study institution.

Conditions

Small Cell Lung Cancer (SCLC)
Neuroendocrine (NE) Tumors
Large Cell Neuroendocrine (NE) Tumors

Interventions

DRUG: Rhenium Re 188-P2045

Sponsor

University of Maryland, Baltimore